Financhill
Buy
54

ESTA Quote, Financials, Valuation and Earnings

Last price:
$33.24
Seasonality move :
-1.6%
Day range:
$32.25 - $33.56
52-week range:
$26.56 - $60.12
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.62x
P/B ratio:
17.98x
Volume:
475.5K
Avg. volume:
601K
1-year change:
-39.28%
Market cap:
$954.6M
Revenue:
$166M
EPS (TTM):
-$2.98

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ESTA
Establishment Labs Holdings
$41.1M -$0.83 17.52% -12.72% $55.00
CVM
CEL-SCI
-- -- -- -- $8.00
IGC
IGC Pharma
$305K -$0.02 3.39% -50% $3.88
NBY
NovaBay Pharmaceuticals
$3M -$0.24 14.03% -95.43% $0.85
PLX
Protalix BioTherapeutics
$21.6M -- 476.31% -- $14.50
VTRS
Viatris
$3.2B $0.49 -8.59% 467.52% $11.7471
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ESTA
Establishment Labs Holdings
$33.02 $55.00 $954.6M -- $0.00 0% 5.62x
CVM
CEL-SCI
$0.25 $8.00 $19M -- $0.00 0% --
IGC
IGC Pharma
$0.29 $3.88 $23.2M -- $0.00 0% 17.11x
NBY
NovaBay Pharmaceuticals
$0.58 $0.85 $3.4M -- $0.00 0% 0.16x
PLX
Protalix BioTherapeutics
$2.73 $14.50 $213M 91.00x $0.00 0% 4.24x
VTRS
Viatris
$8.4800 $11.7471 $10.1B -- $0.12 5.66% 0.69x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ESTA
Establishment Labs Holdings
80.53% -0.370 16.56% 2.28x
CVM
CEL-SCI
-- 1.145 -- --
IGC
IGC Pharma
2.1% -0.278 0.51% 0.21x
NBY
NovaBay Pharmaceuticals
4.54% -0.186 1.51% 0.75x
PLX
Protalix BioTherapeutics
-- 1.057 -- 1.47x
VTRS
Viatris
42.97% 0.971 94.47% 0.80x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ESTA
Establishment Labs Holdings
$30.5M -$18.7M -35.4% -205.2% -67.37% -$22.5M
CVM
CEL-SCI
-- -$6.9M -- -- -- -$4.2M
IGC
IGC Pharma
$104K -$1.9M -114.2% -116.24% -730.74% -$1.4M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
PLX
Protalix BioTherapeutics
$14.3M $7.2M 6.41% 8.75% 40.19% $3.6M
VTRS
Viatris
$1.2B -$38.2M -1.75% -3.22% -11.52% $329.3M

Establishment Labs Holdings vs. Competitors

  • Which has Higher Returns ESTA or CVM?

    CEL-SCI has a net margin of -77.57% compared to Establishment Labs Holdings's net margin of --. Establishment Labs Holdings's return on equity of -205.2% beat CEL-SCI's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ESTA
    Establishment Labs Holdings
    68.5% -$1.19 $272.7M
    CVM
    CEL-SCI
    -- -$0.11 --
  • What do Analysts Say About ESTA or CVM?

    Establishment Labs Holdings has a consensus price target of $55.00, signalling upside risk potential of 66.57%. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 3149.39%. Given that CEL-SCI has higher upside potential than Establishment Labs Holdings, analysts believe CEL-SCI is more attractive than Establishment Labs Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    ESTA
    Establishment Labs Holdings
    5 2 0
    CVM
    CEL-SCI
    1 0 0
  • Is ESTA or CVM More Risky?

    Establishment Labs Holdings has a beta of 0.732, which suggesting that the stock is 26.804% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.498, suggesting its less volatile than the S&P 500 by 50.196%.

  • Which is a Better Dividend Stock ESTA or CVM?

    Establishment Labs Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Establishment Labs Holdings pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ESTA or CVM?

    Establishment Labs Holdings quarterly revenues are $44.5M, which are larger than CEL-SCI quarterly revenues of --. Establishment Labs Holdings's net income of -$34.5M is lower than CEL-SCI's net income of -$7.1M. Notably, Establishment Labs Holdings's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Establishment Labs Holdings is 5.62x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ESTA
    Establishment Labs Holdings
    5.62x -- $44.5M -$34.5M
    CVM
    CEL-SCI
    -- -- -- -$7.1M
  • Which has Higher Returns ESTA or IGC?

    IGC Pharma has a net margin of -77.57% compared to Establishment Labs Holdings's net margin of -711.67%. Establishment Labs Holdings's return on equity of -205.2% beat IGC Pharma's return on equity of -116.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    ESTA
    Establishment Labs Holdings
    68.5% -$1.19 $272.7M
    IGC
    IGC Pharma
    40.47% -$0.02 $6.4M
  • What do Analysts Say About ESTA or IGC?

    Establishment Labs Holdings has a consensus price target of $55.00, signalling upside risk potential of 66.57%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1231.62%. Given that IGC Pharma has higher upside potential than Establishment Labs Holdings, analysts believe IGC Pharma is more attractive than Establishment Labs Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    ESTA
    Establishment Labs Holdings
    5 2 0
    IGC
    IGC Pharma
    2 0 0
  • Is ESTA or IGC More Risky?

    Establishment Labs Holdings has a beta of 0.732, which suggesting that the stock is 26.804% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.503, suggesting its more volatile than the S&P 500 by 50.252%.

  • Which is a Better Dividend Stock ESTA or IGC?

    Establishment Labs Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Establishment Labs Holdings pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ESTA or IGC?

    Establishment Labs Holdings quarterly revenues are $44.5M, which are larger than IGC Pharma quarterly revenues of $257K. Establishment Labs Holdings's net income of -$34.5M is lower than IGC Pharma's net income of -$1.8M. Notably, Establishment Labs Holdings's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Establishment Labs Holdings is 5.62x versus 17.11x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ESTA
    Establishment Labs Holdings
    5.62x -- $44.5M -$34.5M
    IGC
    IGC Pharma
    17.11x -- $257K -$1.8M
  • Which has Higher Returns ESTA or NBY?

    NovaBay Pharmaceuticals has a net margin of -77.57% compared to Establishment Labs Holdings's net margin of -49.65%. Establishment Labs Holdings's return on equity of -205.2% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    ESTA
    Establishment Labs Holdings
    68.5% -$1.19 $272.7M
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About ESTA or NBY?

    Establishment Labs Holdings has a consensus price target of $55.00, signalling upside risk potential of 66.57%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 46.43%. Given that Establishment Labs Holdings has higher upside potential than NovaBay Pharmaceuticals, analysts believe Establishment Labs Holdings is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ESTA
    Establishment Labs Holdings
    5 2 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is ESTA or NBY More Risky?

    Establishment Labs Holdings has a beta of 0.732, which suggesting that the stock is 26.804% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

  • Which is a Better Dividend Stock ESTA or NBY?

    Establishment Labs Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Establishment Labs Holdings pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ESTA or NBY?

    Establishment Labs Holdings quarterly revenues are $44.5M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Establishment Labs Holdings's net income of -$34.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Establishment Labs Holdings's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Establishment Labs Holdings is 5.62x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ESTA
    Establishment Labs Holdings
    5.62x -- $44.5M -$34.5M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M -$1.2M
  • Which has Higher Returns ESTA or PLX?

    Protalix BioTherapeutics has a net margin of -77.57% compared to Establishment Labs Holdings's net margin of 35.65%. Establishment Labs Holdings's return on equity of -205.2% beat Protalix BioTherapeutics's return on equity of 8.75%.

    Company Gross Margin Earnings Per Share Invested Capital
    ESTA
    Establishment Labs Holdings
    68.5% -$1.19 $272.7M
    PLX
    Protalix BioTherapeutics
    78.67% $0.09 $43.2M
  • What do Analysts Say About ESTA or PLX?

    Establishment Labs Holdings has a consensus price target of $55.00, signalling upside risk potential of 66.57%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 431.14%. Given that Protalix BioTherapeutics has higher upside potential than Establishment Labs Holdings, analysts believe Protalix BioTherapeutics is more attractive than Establishment Labs Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    ESTA
    Establishment Labs Holdings
    5 2 0
    PLX
    Protalix BioTherapeutics
    0 0 0
  • Is ESTA or PLX More Risky?

    Establishment Labs Holdings has a beta of 0.732, which suggesting that the stock is 26.804% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.048, suggesting its less volatile than the S&P 500 by 104.824%.

  • Which is a Better Dividend Stock ESTA or PLX?

    Establishment Labs Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Establishment Labs Holdings pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ESTA or PLX?

    Establishment Labs Holdings quarterly revenues are $44.5M, which are larger than Protalix BioTherapeutics quarterly revenues of $18.2M. Establishment Labs Holdings's net income of -$34.5M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Establishment Labs Holdings's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 91.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Establishment Labs Holdings is 5.62x versus 4.24x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ESTA
    Establishment Labs Holdings
    5.62x -- $44.5M -$34.5M
    PLX
    Protalix BioTherapeutics
    4.24x 91.00x $18.2M $6.5M
  • Which has Higher Returns ESTA or VTRS?

    Viatris has a net margin of -77.57% compared to Establishment Labs Holdings's net margin of -14.64%. Establishment Labs Holdings's return on equity of -205.2% beat Viatris's return on equity of -3.22%.

    Company Gross Margin Earnings Per Share Invested Capital
    ESTA
    Establishment Labs Holdings
    68.5% -$1.19 $272.7M
    VTRS
    Viatris
    34.44% -$0.43 $32.7B
  • What do Analysts Say About ESTA or VTRS?

    Establishment Labs Holdings has a consensus price target of $55.00, signalling upside risk potential of 66.57%. On the other hand Viatris has an analysts' consensus of $11.7471 which suggests that it could grow by 38.53%. Given that Establishment Labs Holdings has higher upside potential than Viatris, analysts believe Establishment Labs Holdings is more attractive than Viatris.

    Company Buy Ratings Hold Ratings Sell Ratings
    ESTA
    Establishment Labs Holdings
    5 2 0
    VTRS
    Viatris
    2 5 0
  • Is ESTA or VTRS More Risky?

    Establishment Labs Holdings has a beta of 0.732, which suggesting that the stock is 26.804% less volatile than S&P 500. In comparison Viatris has a beta of 0.887, suggesting its less volatile than the S&P 500 by 11.265%.

  • Which is a Better Dividend Stock ESTA or VTRS?

    Establishment Labs Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viatris offers a yield of 5.66% to investors and pays a quarterly dividend of $0.12 per share. Establishment Labs Holdings pays -- of its earnings as a dividend. Viatris pays out -90.63% of its earnings as a dividend.

  • Which has Better Financial Ratios ESTA or VTRS?

    Establishment Labs Holdings quarterly revenues are $44.5M, which are smaller than Viatris quarterly revenues of $3.5B. Establishment Labs Holdings's net income of -$34.5M is higher than Viatris's net income of -$516.5M. Notably, Establishment Labs Holdings's price-to-earnings ratio is -- while Viatris's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Establishment Labs Holdings is 5.62x versus 0.69x for Viatris. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ESTA
    Establishment Labs Holdings
    5.62x -- $44.5M -$34.5M
    VTRS
    Viatris
    0.69x -- $3.5B -$516.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is it Safe to Invest in Google With OpenAI Threats?
Is it Safe to Invest in Google With OpenAI Threats?

For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…

Is Broadcom Stock a Millionaire Maker?
Is Broadcom Stock a Millionaire Maker?

Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…

Is Berkshire The Best Stock to Buy in a Bad Market?
Is Berkshire The Best Stock to Buy in a Bad Market?

Berkshire Hathaway (NYSE:BRK.A, BRK.B) has historically been one of the…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Buy
60
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Alerts

Buy
60
RGC alert for May 7

Regencell Bioscience Holdings [RGC] is up 19.21% over the past day.

Buy
77
FARO alert for May 7

Faro Technologies [FARO] is up 0.12% over the past day.

Buy
53
SRPT alert for May 7

Sarepta Therapeutics [SRPT] is down 19.29% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock